Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder by Cardoner, Narcís et al.
Effects of Duloxetine Treatment on Brain Response to
Painful Stimulation in Major Depressive Disorder
Marina Lo´pez-Sola`1,2, Jesus Pujol*,1,3, Rosa Herna´ndez-Ribas1,4,5, Ben J Harrison1,6, Oren Contreras-
Rodrı´guez1,7, Carles Soriano-Mas1,7, Joan Deus1,8, He´ctor Ortiz1, Jose´ M Mencho´n4,5, Julio Vallejo2,5
and Narcı´s Cardoner1,4,5
1Institut d’Alta Tecnologia–PRBB, CRC Hospital del Mar, Barcelona, Spain; 2Faculty of Medicine, Department of Clinical Sciences, University of
Barcelona, Barcelona, Spain; 3Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain;
4Department of Psychiatry, Bellvitge University Hospital–IDIBELL, Barcelona, Spain; 5Instituto de Salud Carlos III, Centro de Investigacio´n en Red
de Salud Mental (CIBERSAM), Madrid, Spain; 6Department of Psychiatry, Melbourne Neuropsychiatry Centre, The University of Melbourne,
Melbourne, Victoria, Australia; 7Human Pharmacology and Neurosciences Department, Fundacio´ IMIM-PRBB, Barcelona, Spain; 8Department of
Clinical and Health Psychology, Autonomous University of Barcelona, Barcelona, Spain
Major depressive disorder (MDD) is characterized by a constellation of affective, cognitive, and somatic symptoms associated with
functional abnormalities in relevant brain systems. Painful stimuli are primarily stressful and can trigger consistent responses in brain
regions highly overlapping with the regions altered in MDD patients. Duloxetine has proven to be effective in treating both core
emotional symptoms and somatic complaints in depression. This study aimed to assess the effects of duloxetine treatment on brain
response to painful stimulation in MDD patients. A total of 13 patients and a reference group of 20 healthy subjects were assessed on
three occasions (baseline, treatment week 1, and week 8) with functional magnetic resonance imaging (fMRI) during local application of
painful heat stimulation. Treatment with duloxetine was associated with a significant reduction in brain responses to painful stimulation in
MDD patients in regions generally showing abnormally enhanced activation at baseline. Clinical improvement was associated with pain-
related activation reductions in the pregenual anterior cingulate cortex, right prefrontal cortex, and pons. Pontine changes were
specifically related to clinical remission. Increased baseline activations in the right prefrontal cortex and reduced deactivations in the
subgenual anterior cingulate cortex predicted treatment responders at week 8. This is the first fMRI study addressed to assess the effect
of duloxetine in MDD. As a novel approach, the application of painful stimulation as a basic neural stressor proved to be effective in
mapping brain response changes associated with antidepressant treatment and brain correlates of symptom improvement in regions of
special relevance to MDD pathophysiology.
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INTRODUCTION
Major depression is a frequent and disabling psychiatric
disorder (World Health Organization, 2001) characterized
by a constellation of mood, cognitive, psychomotor, and
somatic symptoms (American Psychiatric Association,
2000). Neuroimaging has contributed to current under-
standing of major depressive disorder (MDD) pathophy-
siology, suggesting a global misbalance in the neural
systems that serve such major aspects of brain function
(Drevets, 2000; Mayberg, 2003; Price and Drevets, 2010;
Sheline, 2003).
Painful stimuli are primarily salient and threatening, and
normally provoke rapid withdrawal and stress-related
responses (Price, 2000). Functional magnetic resonance
imaging (fMRI) has confirmed the involvement of a
widespread brain network in processing noxious stimula-
tion including the somatosensory system, limbic and
paralimbic regions related to the affective experience of
pain, and prefrontal regulatory areas modulating the entire
brain response (Apkarian et al, 2005; Lo´pez-Sola` et al, 2010;
Wiech et al, 2008a). As painful stimulation typically evokes
an integrated response involving brain regions that are
relevant to MDD pathophysiology (Drevets, 2000; Mayberg,
2003; Sheline, 2003), functional neuroimaging using
pain paradigms may provide the opportunity to challenge
such regions, both for the purpose of investigating MDD
abnormalities in response to a basic neural stressor
(Ba¨r et al, 2007; Strigo et al, 2008), and also, potentially,
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for providing objective biological markers of the effects of
antidepressant treatment.
The interaction between major depression and pain
symptoms appears to be a growing focus of interest in
MDD research. Clinical pain complaints have significantly
higher mean prevalence in MDD patients (65% as reviewed
by Bair et al, 2003) compared with the general population
(24–37%, Regier et al, 1984), and furthermore, the presence
of pain complaints in MDD patients is associated with
greater MDD severity and refractoriness (Bair et al, 2003).
In addition, mood symptoms and somatic pain in depres-
sion have been shown to improve simultaneously (Blier and
Abbott, 2001). Recent evidence suggests that dual seroto-
nine and norepinephrine reuptake inhibitors (such as
duloxetine, Trivedi et al, 2008) are effective antidepressants
relieving both mood symptoms and somatic complaints in
MDD (Gupta et al, 2007). Specifically for the case of
duloxetine, several studies have suggested that early
symptomatic improvement may already be noticeable after
1–2 weeks of treatment (Hirschfeld et al, 2005; Nemeroff
et al, 2002; Shelton et al, 2007). In contrast to the described
close clinical association between major depression and
pain complaints, it has been suggested that depressed
patients are less sensitive to experimentally induced pain on
the skin (Ba¨r et al, 2005), although the neural basis for this
paradox is still rather unknown (Ba¨r et al, 2007). In
addition, the effect of antidepressant treatment on experi-
mental thermal pain perception and the associated brain
responses has not been explored to date.
Neuroimaging techniques have been successfully used to
assess the effects of various drugs on baseline brain
metabolism and on the cerebral response to specific
cognitive and emotional stimuli (Drevets et al, 2008a;
Mayberg, 2003; Rigucci et al, 2009). Nevertheless, despite its
potential interest, it is noteworthy that imaging paradigms
based on painful stimulation have not been used to
investigate the effects of antidepressant agents.
This fMRI study aimed to assess the effects of duloxetine
treatment on brain response to heat painful stimulation in
MDD patients. The study design included an fMRI
assessment at baselineFpretreatmentFand assessments
following 1 week and 8 weeks of treatment. Brain activations
in MDD patients were compared with the activations
obtained in a reference group of healthy subjects who were
also assessed three times to control for task-repetition
effects. Brain correlates of clinical improvement were
investigated for both core and somatic depression symp-
toms. A specific analysis was also conducted to identify
baseline brain imaging predictors of clinical response to
treatment. Finally, correlations between experimental pain
ratings and fMRI treatment effects on brain responses to
pain were also investigated.
MATERIALS AND METHODS
Subjects
Fifteen patients were consecutively recruited from the Mood
Disorders Unit of the University Hospital of Bellvitge. All
patients met DSM-IV criteria for MDD with no psychotic
features. MDD patients were assessed using the Structured
Clinical Interview for DSM-IV Axis I DisordersFClinician
Version (SCID; First et al, 1997) that was conducted by two
senior psychiatrists who reached a consensus for all items
and also for the compliance of inclusion/exclusion criteria.
At inclusion, all patients had a Hamilton Depression Scale
(HAM-D 17; Hamilton, 1960, 1967) score X18. Exclusion
criteria included the presence or history of other axis I
diagnoses and relevant medical or neurological disorders
including chronic pain syndromes, and abnormal clinical
MRI on radiological inspection. From the original
15-subject sample, one patient was excluded as she was
unable to complete the first fMRI session and another
patient voluntarily left the study after the first MRI
assessment. The remaining 13 patients underwent both
basal and 8-week reassessment and made up our final study
patient sample. One of these 13 patients, however, was
unable to complete the week 1 fMRI session as she felt
temporarily sick on the assessment day. Table 1 shows the
clinical characteristics of the final 13-patient sample.
A comparison group of 21 healthy volunteers also
participated in the study. A SCID was carried out to discard
the presence of axis I disorders, and also a complete medical
interview was performed to exclude subjects with relevant
medical or neurological disorders, history of substance
abuse and psychiatric illness, and chronic pain syndromes.
From the original sample, one subject was excluded due to
excessive movement inside the scanner (translation move-
ment in the z axis 43 mm) during the baseline fMRI
assessment. A total of 20 subjects made up the control
sample, although technical issues with the thermal stimu-
lator compromised the use of one subject’s fMRI data from
the week 1 assessment. Age, gender, handedness, and years
of education are reported in Table 1. MDD patients and
control subjects did not differ on these variables. All
patients and control subjects gave written informed consent
to participate in the study, which was approved by the
research and ethics committee of the University Hospital of
Bellvitge.
Study Design
For all patients, the study included an antidepressant
medication washout of 15 days before treatment onset.
Patients received antidepressant treatment with oral dulox-
etine, a serotonin-norepinephrine reuptake inhibitor, start-
ing at 60 mg per day in a single dosage for 4 full weeks. After
week 4, dose increases (up to 120 mg per day) were
prescribed on the basis of patients’ response when both
senior psychiatrists coincided in their clinical judgment. All
patients underwent weekly clinical assessments throughout
the study period. The following clinical scales were used to
assess mood, somatic, and general treatment-related response:
HAM-D-17 (Hamilton, 1960, 1967), Brief Pain Inventory
(Cleeland and Ryan, 1994), Symptom QuestionnaireF
Somatic Subscale (Kellner, 1987), and the Clinical Global
Impression of Severity (Guy, 1976).
The study consisted of three fMRI assessments, which
were carried out at week 0 (before treatment), and following
1 and 8 weeks of treatment. Control subjects also underwent
fMRI assessments at baseline, week 1 and week 8, which
served to control for task-repetition effects on brain
responses to painful stimulation.
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Stimulus
The Contact Heat-Evoked Potential Stimulator (CHEPS)
system was used, which has been designed to provide
controlled thermal stimuli (CHEPS; Medoc, Advanced
Medical Systems, Israel). This system is able to provoke
pain by direct stimulation of AD and C nociceptive fibers on
a relatively large skin area (by the 27 mm diameter
thermode) through very rapid local heating (701C per
second rate). In our experiment, painful heat stimulation
was applied to the right volar forearm in 10-s blocks each
including eleven 501C spikes (full-width at half-maximum
duration of each spike: 125 ms), starting from a baseline
temperature of 321C.
In a preliminary session, each subject was trained to rate
their perceived pain intensity using a numerical rating scale
ranging from 0 (‘no pain’) to 100 (‘the worst pain’), and
perceived unpleasantness using a nine-point verbal de-
scriptor scale ranging from ‘not at all unpleasant’ to
‘extremely unpleasant’ when receiving two full (11 spikes)
stimulation blocks.
fMRI Pain Paradigm
A block design was used consisting of three conditions per
stimulation cycle repeated 12 times during a 7-min run: a
rest condition with pseudorandom variable duration
(duration range: 12–26 s), a 6-s anticipatory condition that
began with a brief auditory stimulus (600-ms tone) cuing
the subsequent pain condition, and the actual 10-s painful
condition (involving the application of the 501C spike
stimuli). Immediately after the entire fMRI sequence was
completed, each subject rated the overall pain intensity and
unpleasantness experienced during the 12 painful stimula-
tion cycles.
MRI Acquisition
A 1.5 Tesla Signa system (General Electric, Milwaukee, WI)
equipped with an eight-channel phased-array head coil and
single-shot echoplanar imaging (EPI) software was used.
Functional sequences consisted of gradient-recalled acqui-
sitions in the steady state (time of repetition, 2000 ms; time
of echo, 50 ms; pulse angle, 901) within a field of view of
24 cm, a 64 64 pixel matrix, and a slice thickness of 4 mm
(interslice gap, 1.5 mm). Twenty-two slices parallel to the
anterior-posterior commissure line covered the whole
brain. The sequence included four additional dummy
volumes to allow the magnetization to reach equilibrium.
Image Preprocessing
Imaging data were processed using MATLAB version 7 (The
MathWorks, Natick, MA) and Statistical Parametric Map-
ping software (SPM5; The Welcome Department of Imaging
Neuroscience, London). Image preprocessing involved
motion correction, spatial normalization, and smoothing
using a Gaussian filter (full-width at half-maximum, 8 mm).
Data were normalized to the standard SPM-EPI template
and resliced into 2 mm isotropic voxels in Montreal
Neurological Institute space.
Statistical Analyses
Brain responses to painful stimulation and group
comparisons. Our analyses aimed to identify (1) between-
group differences in brain activation at baseline (pretreat-
ment), (2) treatment effects at week 1, (3) treatment effects
at week 8, and (4) the pattern of correlations between
clinical measurements (and experimental pain ratings) and
fMRI treatment effects.
Table 1 Main Characteristics of the Study Sample
MDD patients Controls T/v2 p
Age at inclusion (mean±SD years) 44.6±8.3 47.2±7.7 0.82/ 0.41
Gender (female/male) 11/2 15/5 /0.64 0.52
Handedness (right handed/left handed) 12/1 20/0 /1.00 0.34
Years of education (mean±SD years) 11.2±3.2 12.4±2.3 1.16/ 0.25
Age at onset (range, mean±SD) 18–47, 36.85±8.53 NA NA NA
Total no. of episodes (range, mean±SD) 0–6, 2.23±2.13 NA NA NA
Current episode duration (range, mean±SD days) 110–1080, 414±340 NA NA NA
AD treatment before washout (%yes/%no) 84.6/15.4% NA NA NA
Antidepressant type before washout (type, no. of patients) SSRI, 8; TCA, 2; SNRI, 1 NA NA NA
HAM-D 17a 21.3±2.6 0.18±0.5 37.39/ o0.0001
BPIa 6.8±1.1 2.4±3.0 5.90/ o0.0001
SQ-SSa 15.6±4.0 2.1±1.8 11.50/ o0.0001
CGI severitya 4.5±0.8 1±0 16.07/ o0.0001
Abbreviations: AD, antidepressant; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; SNRI, serotonin-norepinephrine reuptake inhibitor;
HAM-D 17, Hamilton Depression Rating Scale, 17-item version; BPI, Brief Pain Inventory, maximum pain during the week; SQ-SS, Symptom Questionnaire,
Somatic Subscale; CGI Severity, Clinical Global Impression of Severity, NA, nonapplicable.
aAll measurements were obtained at baseline fMRI (before treatment onset).
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Single-subject first-level analyses were implemented in
SPM5 to model fMRI time series using four box-car
regressors; two representing anticipation and painful
stimulation periods, and two representing the rest period
divided into two parts: a 6-s post-stimulation period and a
variable (6–20 s) remaining rest period, considering a
hemodynamic delay of 4 s. We explicitly modeled the
post-stimulation period (6-s interval after each stimulation
block), as brain activation may persist during this period
(Lo´pez-Sola` et al, 2010; Moulton et al, 2005; Pujol et al,
2009) and may therefore alter the reference baseline with
noncontrolled remaining activation. A contrast image
showing fMRI signal differences between the painful
stimulation condition and the second part of the rest
period (modeled by the corresponding box-car regressors in
SPM5) was calculated for each subject.
The contrast images were then carried forward to
subsequent second-level random-effects (group) analyses.
One-sample t-statistic maps were calculated to obtain
baseline (pretreatment) activation (and deactivation) pat-
terns for each group, and a two-sample t-test was performed
to map between-group baseline brain activation (and
deactivation) differences. To assess treatment effects on
brain response to pain, we performed two separate (week 1
and week 8) second-level mixed ANOVA analyses including
the within-subject factor ‘time moment’ (baseline vs
reassessment), and the intersubject factor ‘group’ (patient
vs control) as independent variables. Group-by-time inter-
action t-statistic maps were then calculated to identify
activation changes that were greater in MDD patients than
in healthy control subjects.
For the sake of simplicity we do not report treatment
effects on the anticipatory period (before actual painful
stimulation onset) as the complete pattern followed the same
direction as treatment effects occurring in response to actual
painful stimulation, thus adding only marginal information
considering the purposes of the study and space limitation.
Correlation analyses between clinical and fMRI treatment
effects. Specific correlation analyses were performed in
SPM5 to test for linear relationships between clinical
improvement in the two symptomatic dimensions of
interest, ie, core emotional and somatic symptoms (mea-
sured as reductions in Core (items 1, 2, 3, 7, and 8) and
Somatization Subscales (10, 11, 12, 13, 15, and 17) of the
HAM-D 17) and fMRI brain activation changes at weeks 1
and 8 in relation to baseline. These exploratory correlation
analyses were carried out for regions showing significant
treatment effects at weeks 1 and 8 (regions showing
significant interaction results from the mixed ANOVA
models (reported in Table 3).
An exploratory two-sample t-test analysis was addition-
ally performed to assess treatment-related fMRI activation
changes associated with remission (binary factor defined by
HAM-D 17 scores below 7 or X7), by comparing the
‘baseline minus week 8 activation’ contrast images between
remitting and nonremitting patients (for the regions
showing significant treatment effects after 8 weeks).
Imaging predictors of clinical response. To specifically test
whether baseline (pretreatment) regional activations were
able to predict positive clinical responders to duloxetine
(measured as 50% reductions in the HAM-D 17 total score
from baseline to week 8), we performed an exploratory two-
sample t-test analysis to compare the patterns of baseline
activation of clinical responders and nonresponders (also
for the regions showing significant treatment effects after 8
weeks).
Correlation analyses between pain ratings and fMRI
treatment effects. To investigate the relationship between
experimental pain perception and brain activation in
regions showing significant treatment effects in MDD, we
conducted additional correlation analyses in SPM5. For
both intensity and unpleasantness ratings, two models were
estimated in MDD patients to: (1) correlate changes in
subjective pain ratings with changes in fMRI responses
from baseline to week 8 and (2) correlate subjective pain
scores and fMRI brain response measurements at week 8.
The analyses were carried out for regions showing
significant treatment effects at week 8 (regions showing
significant interaction results from the mixed ANOVA
model (reported in Table 3).
Thresholding criteria. Baseline group activation (and deactiva-
tion) results were thresholded at pFalse Discovery RateFDR
o0.05 whole-brain corrected. Between-group differences,
interaction effects, and correlation analyses were considered
significant when involving a minimum cluster extension of
200 voxels (1600 mm3) at po0.05 uncorrected. The use of
a combined p-value/cluster extension thresholding approach
has been suggested to provide a more desirable balance
between type I and type II error rates (Lieberman and
Cunningham, 2009). For the brainstem (as it is a small
structure), a more lenient extension threshold (cluster 4100
voxels) was used.
RESULTS
Clinical Response to Treatment
Supplementary Table S1 shows patients’ response to
treatment measured as changes in the selected clinical
scales. All in all, a modest, though significant, improvement
was observed after 1 week of treatment in most scales.
Differences were robust after 8 weeks of treatment in all
measurements. At the end of the 8-week treatment period,
nine out of thirteen patients met the criterion for clinical
response to treatment and six of them met the criterion for
clinical remission.
Subjective Pain Scores During fMRI
Major depressive disorder patients and control subjects did
not differ as to the reported amount of subjective pain
intensity (mean±SD for patients: 5.8±2.4 and control
subjects: 6.7±1.8; t¼ 1.27, p¼ 0.21) and unpleasantness
(patients, 3.7±1.7; control subjects, 4.6±1.5; t¼ 1.6,
p¼ 0.13) during baseline fMRI assessment, although
patients showed the lowest values for both measurements.
We found no significant group-by-time interaction effect
when comparing baseline and week 1 subjective pain scores
(intensity F¼ 0.72, p¼ 0.40; unpleasantness F¼ 0.04,
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p¼ 0.85). Nevertheless, significant group-by-time interac-
tions for pain intensity (F¼ 5.21, p¼ 0.03) and unpleasant-
ness (F¼ 7.64, p¼ 0.01) were found when comparing
baseline and week 8 measures. Post hoc comparisons
indicated that although control subjects did not show
significant changes from baseline to week 8 reassessment
(intensity: t¼1.24, p¼ 0.23; unpleasantness: t¼1.68,
p¼ 0.11), patients had a tendency to report increased pain
intensity (t¼ 1.86, p¼ 0.088) and showed significantly
higher unpleasantness scores (t¼ 2.38, p¼ 0.035) after this
period. Interestingly, we found a significant correlation
between the reduction in core emotional MDD symptoms
after treatment (baseline to week 8) and the enhancement of
pain unpleasantness ratings (r¼0.59, p¼ 0.03), and a
weaker association for perceived intensity (r¼0.44,
p¼ 0.13).
Brain Response to Painful Heat Stimulation: Baseline
Assessment
Baseline brain responses to painful heat stimulation are
reported in Table 2 and Figure 1. For both study groups,
brain response was characterized by significant activation
in bilateral insulae extending to basal ganglia, parietal and
frontal opercula, ACC-supplementary motor area (SMA),
prefrontal cortex, and cerebellum. The patient group
additionally showed significant activation in the middle
temporal gyrus (Brodmann area (BA) 22) and in the
hypothalamic–midbrain region. Significant reductions in
fMRI signal during painful stimulation compared with rest
(deactivations) were only identified in the control subject
group and involved the subgenual–pregenual ACC and
extended medial prefrontal cortex.
Compared with control subjects, the MDD group showed
greater baseline activation in bilateral insulae, frontal and
temporal opercula, ventral basal ganglia, hypothalamic
region, medial prefrontal cortex, left hippocampus, and
middle temporal gyrus (Table 2; Figure 2a). Patients also
showed significantly reduced deactivation (ie, abnormal
persistence of activity during stimulation) in a large area
involving the subgenual and pregenual ACC and extended
medial prefrontal regions (Table 2; Figure 2b). We found no
regions of significantly greater activation in the control
group when compared with MDD patients.
Treatment Effects on Brain Response to Painful
Stimulation
Significant group-by-time interactions were observed from
baseline to week 1 fMRI assessments revealing a general
effect of brain activation reductions in MDD patients and
the opposite tendency in control subjects (Table 3; Supple-
mentary Table S2; Figure 3; Supplementary Figure S1).
Regions showing a significant interaction effect largely
coincided with regions showing enhanced baseline activa-
tion (or reduced deactivation) in MDD patients compared
with control subjects (bilateral insulae, frontal and temporal
opercula, basal ganglia, hypothalamic region, ventromedial
prefrontal cortex, left hippocampus, middle temporal gyrus,
and subgenual–pregenual ACC regions). In addition, group-
by-time interactions were significant in the dorsolateral
prefrontal cortex (BA 9/10).
Significant group-by-time interactions were again ob-
served from baseline to week 8, with group changes showing
the direction observed in week 1 interaction analysis and
involving a similar region network (Table 3; Supplementary
Table S3; Figure 3; Supplementary Figure S1). In addition,
an interaction effect was observed along the brainstem
including anterior and posterior parts of the pons.
Correlations Between Clinical and fMRI Treatment Effects
A specific analysis was carried out to assess the correlation
between clinical improvement in both core emotional and
Table 2 Brain Response to Painful Heat in MDD and Control
Subjects and Between-Group Differences
Controls activations X: Y: Z k t pFDR
Insula–opercula 36 0 8 2252 6.14 0.008
40 34 2 2071 7.39 0.007
Prefrontal cortex 36 32 12 132 4.20 0.022
46 34 36 581 5.26 0.010
Basal ganglia 30 8 6 302 5.10 0.011
30 6 6 233 4.87 0.013
ACC-SMA 6 20 36 1666 4.47 0.018
Cerebellum 4 50 18 468 5.28 0.010
Controls deactivations X : Y : Z k t pFDR
Subg., Preg. ACC 2 46 14 1446 5.59 0.003
Patients activations X : Y : Z k t pFDR
Insula–opercula
42 10 0 4056 7.37 0.037
50 8 4 3990 6.68 0.037
Prefrontal cortex 58 2 42 200 4.36 0.038
54 0 56 305 5.57 0.037
Basal ganglia 30 6 0 354 4.63 0.041
28 14 2 414 4.43 0.041
ACC-SMA 8 12 44 2100 5.75 0.037
Cerebellum 4 46 24 1717 6.10 0.037
Middle temporal gyrus 68 42 8 298 5.30 0.037
Hypothal. region–midbrain 4 4 14 132 3.89 0.043
Patients4controls X : Y : Z k t pUnc.
Increased activations
Post. Ins.–Temp. Operc.–HPC 46 26 10 1249 3.18 0.002
40 14 6 2042 4.24 o0.0005
Ant. Ins.–frontal Operc. 24 24 6 585 3.01 0.002
Basal G.–Med. PFC–Hypothal.
region
4 16 16 1146 3.50 0.001
Middle temp. gyrus 62 42 4 569 3.28 0.001
Reduced deactivations
Subg., Preg. ACC 4 18 18 2185 3.91 o0.0005
Abbreviations: k, cluster size; FDR, false discovery rate whole-brain corrected;
Unc., uncorrected; ACC, anterior cingulate cortex; SMA, supplementary motor
area; Hypothal., hypothalamic; Post., posterior; Ins., insula; Temp., temporal;
Operc., operculum; HPC, hippocampus; Ant., anterior; Med., medial. Subg.,
subgenual; Preg., pregenual.
Coordinates (X: Y: Z) are given in Montreal Neurological Institute Atlas space.
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somatic symptoms (using the Core and Somatization
Subscales of the HAM-D 17, respectively) and fMRI
treatment-related changes. This analysis was limited to the
regions that showed significant treatment effects. We found
that reductions in core MDD symptoms after 1 week of
treatment were significantly correlated with activation
reductions (ie, deactivation increases) in the pregenual
ACC region (ventral BA24 and BA32), which showed an
abnormal persistence of activity during stimulation at
baseline. Reductions in somatic symptoms were signifi-
cantly correlated with activation reductions in the right
dorsolateral prefrontal cortex (BA 9, Supplementary
Table S4; Supplementary Figure S2).
Improvement in core MDD symptoms after 8 weeks of
treatment correlated with activation reductions in the right
dorsolateral prefrontal cortex (BA 9) and left insulo-
opercular region, whereas the improvement in somatic
symptoms after this period was associated with activation
reductions in the pons (Supplementary Table S4; Supple-
mentary Figure S2).
The categorical analysis assessing fMRI treatment-related
changes associated with remission showed that remitting
Figure 1 Brain activation and deactivation patterns for healthy controls and MDD patients in response to painful heat stimulation. (a) Activation pattern
for healthy controls. (b) Deactivation pattern for healthy controls. (c) Activation pattern for MDD patients. (d) Deactivation pattern for MDD patients. All
depicted voxels show po0.05FDR corrected. Images are shown in the neurological convention.
Figure 2 Regions showing greater activation during painful heat stimulation in Patients. (a) Patients 4controls, assessed within the activation pattern of
the patient group. (b) Patients 4controls, assessed within the deactivation pattern of the control group. Images are shown in the neurological convention.
Extension threshold: 200 voxels. p-Voxel level o0.05 uncorrected.
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(compared with nonremitting) patients had greater activa-
tion reductions in the pons after 8 weeks of treatment
(Supplementary Table S4; Supplementary Figure S3).
fMRI Predictors of Clinical Response to Treatment
We performed an analysis to look specifically for region
activations at baseline fMRI capable of predicting treatment
responders at week 8. We found that increased baseline
activation during painful stimulation in the right dorso-
lateral prefrontal cortex (BA 9) and reduced deactivation in
the subgenual ACC and extended medial prefrontal regions
were significantly associated with positive responses to
treatment (measured as 50% reductions in the HAM-D 17)
(Supplementary Table S4; Supplementary Figure S3).
Correlations Between Experimental Pain Ratings and
fMRI Treatment Effects
This analysis allowed us to map the relationship between
experimental pain perception and brain activation in
regions showing significant treatment effects in MDD.
Although no significant results emerged for the unpleasant-
ness correlation analyses, both the increase in perceived
pain intensity after treatment (score change from baseline
to week 8) and pain intensity scores reported at week 8 were
significantly associated with brain regions modulated by
treatment in MDD patients (Supplementary Table S5;
Supplementary Figure S4). Specifically, (1) increases in
experimental pain intensity from baseline to week 8 were
associated with treatment-related activation reductions in
the right frontal cortex and (2) greater pain intensity
scores at week 8 were significantly associated with greater
Table 3 Treatment Effects on Brain Response to Painful
Stimulation
Region X: Y: Z k t pUnc.
Week 1 treatment effects. Interaction effects (baseline to week 1)
Insula–Operc.–HPC 40 8 14 701 3.46 0.001
48 10 6 761 2.68 0.005
Basal ganglia 12 8 22 204 2.71 0.004
12 4 22 395 2.69 0.005
Hypothal. region–Med. PFC 6 2 16 355 3.88 o0.0001
Middle temp. gyrus 66 36 0 765 3.55 o0.0001
Subg. Preg. ACC 6 50 10 5515 3.86 o0.0001
Dorsolat. PFC 36 22 34 1097 2.78 0.004
20 34 26 1014 3.03 0.002
Week 8 treatment effects. Interaction effects (baseline to week 8)
Anterior Insula–frontal Op. 46 20 2 1039 2.94 0.002
Posterior insula–Temp Op. 44 24 6 281 3.17 0.001
44 16 6 315 2.82 0.003
Hypothal. region–Med. PFC 4 2 16 358 3.05 0.002
Middle Temp. gyrus 60 42 4 473 3.36 0.001
Subg. Preg. ACC 2 22 24 1368 3.70 o0.0001
Dorsolat. PFC 30 48 14 219 2.84 0.003
34 26 34 1002 3.40 0.001
Inferior pons 2 38 36 1717 3.08 0.002
Superior pons 0 20 24 1717 2.92 0.002
Abbreviations: k, cluster size; Unc., uncorrected; Operc., opercula; Op.,
operculum; HPC, hippocampus; Hypothal., hypothalamic; Med., medial;
PFC, prefrontal cortex; Temp., temporal; Subg., subgenual; Preg., pregenual;
ACC, anterior cingulate cortex; Dorsolat., dorsolateral.
Coordinates (X: Y: Z) are given in Montreal Neurological Institute Atlas space.
Figure 3 Group-by-time interaction effects showing significant activation reductions in the MDD group after 1 (baseline to 1 week) and 8 weeks (baseline
to 8 weeks) of receiving treatment when compared with reassessment effects in the healthy control group. Images are shown in the neurological convention.
Extension threshold: 200 voxels. p-Voxel level o0.05 uncorrected.
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subgenual ACC (and extended medial prefrontal cortex)
deactivation magnitudes.
DISCUSSION
Major depressive disorder patients treated with duloxetine
showed a significant reduction in fMRI pain-related
activations (and enhancement of deactivations) when
compared with nontreated control subjects. Relevantly,
most treatment-related imaging changes occurred in
regions showing altered baseline responses to pain in the
patient group. Treatment-related deactivation increases in
the pregenual ACC, and activation reductions in right
prefrontal cortex and pons were associated with MDD
symptom improvement. Pontine changes were specifically
related to MDD clinical remission. Higher baseline activa-
tion in the right prefrontal cortex and lower deactivation in
the subgenual ACC predicted clinical response to treatment
at week 8. Remarkably, these two brain areas also showed a
specific association with the paradoxical increase in
experimental pain perception following treatment in the
MDD group. Moreover, the treatment-related increase in
experimental pain perception was significantly associated
with the observed reduction in core emotional MDD
symptoms.
The MDD group showed significant enhancement of
baseline responses to pain within the insula–operculum–
basal ganglia complex bilaterally, hippocampus, the hy-
pothalamic region, and the surrounding anterior ventro-
medial prefrontal. To the best of our knowledge, only two
studies have directly explored abnormal brain responses to
painful stimulation in MDD patients. Our data are
coincident with the results reported by Ba¨r et al (2007)
showing increased fMRI activations in MDD patients within
several pain-processing regions. In another study, Strigo
et al (2008) assessed pain in young adult MDD patients
during a continuous performance task and again reported
abnormal activations in patients showing increased
responses to pain anticipatory cues in limbic and para-
limbic regions, but mostly reduced activations during actual
pain. Interestingly, their findings may well suggest a
relevant role for attention resources in modulating brain
responses to painful stimulation in MDD patients.
Our baseline analysis may provide relevant new findings
by also indicating that MDD patients failed to deactivate a
relatively large frontal region involving the subgenual–
pregenual ACC and adjacent medial prefrontal areas in
response to painful stimuli. These ventromedial prefrontal
structures, which are a growing focus of interest in MDD
research, are normally highly active in resting-state condi-
tions when attention is primarily self-directed and become
deactivated in response to attention-demanding external
stimulation (Harrison et al, 2008; Raichle et al, 2001).
Interestingly, fMRI studies in MDD assessing brain
responses during emotion processing, judgment and
reappraisal of aversive stimuli (Grimm et al, 2009; Sheline
et al, 2009), and during cognitive-executive tasks (Matthews
et al, 2009; Mitterschiffthaler et al, 2008; Vasic et al, 2009;
Wagner et al, 2006, 2008) have reported a failure to reduce
activity in depressed patients in these medial prefrontal
regions, which has been linked to symptom severity
(Grimm et al, 2009; Matthews et al, 2009). All in all, our
findings, together with previous data, may reflect impaired
effectiveness for patients in disengaging from self-referen-
tial processing.
We observed significant changes in brain responses to
pain after 1 week of treatment manifested as greater
activation reductions in treated MDD patients when
compared with control subjects, mostly within areas
showing abnormally enhanced responses at baseline. The
complete 8-week period of duloxetine treatment was
associated with significant brain activation reductions in a
similar region pattern, together with additional changes in
the brainstem. These late (8-week) brain functional changes
were paralleled by robust clinical improvement in core and
somatic MDD symptoms, which was fully accomplished up
to clinical remission in a relevant proportion of patients. To
the best of our knowledge, there is no previous imaging
study to date assessing the effects of duloxetine on brain
function. Also, this is the first fMRI study using painful
stimulation as a basic neural stressor to map treatment
effects on brain activation and their association with clinical
outcome (one previous study used painful stimulation to
assess the effects of several drug treatments on cerebral
blood flow using SPECT; Graff-Guerrero et al, 2008).
Few studies have evaluated short-term effects of anti-
depressant treatment using neuroimaging tools. A recent
SPECT study reported a broad attenuation of cerebral blood
flow responses to painful stimulation in a group of MDD
patients treated with different antidepressant drugs for 2
weeks (Graff-Guerrero et al, 2008). Another study using an
fMRI paradigm of aversive vs neutral pictures (Davidson
et al, 2003) also found significant fMRI BOLD signal
changes in the insular cortex after 2 weeks of treatment
using the dual reuptake inhibitor venlafaxine. Both studies
also reported significant, albeit mild, reductions in clinical
measurements of MDD severity. Mayberg et al (2000) did
not report any significant clinical responses after 1 week of
fluoxetine treatment, although metabolic changes were
noticed in several cortical and subcortical regions. Our
data coincide with previous studies in showing detectable
imaging changes at early treatment stages when the clinical
effects are typically modest. The potential ability of
neuroimaging for the early detection of brain changes
could be useful in future drug discovery research, mainly if
brain regions relevant to MDD are targeted. In our study,
brain activation reductions after 1 week of duloxetine
treatment included activation changes in regions already
reported in the previous studies (insula, hippocampus, and
basal ganglia), but also in the critical subgenual ACC and in
the dorsolateral prefrontal cortex.
In contrast with the paucity of studies assessing early
brain changes during MDD treatment, imaging assessment
of complete treatment effects has been more comprehen-
sive. A large number of PET and SPECT studies have
provided evidence of treatment-related normalization of
altered baseline patterns of brain metabolic activity in MDD
patients after various treatment strategies (see recent
reviews by Frewen et al, 2008; Mayberg, 2009; Padberg
and George, 2009; Ressler and Mayberg, 2007; Rigucci et al,
2009; Roffman et al, 2005; Schmidt et al, 2008). Less
information, however, is available as to the effects of
antidepressant treatment on altered brain systems in MDD
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when specifically challenged by disease-relevant stimula-
tion. Consistent with our results, fMRI studies using
aversive visual stimulation mostly reported treatment-
related activation reductions (in regions generally showing
abnormally enhanced baseline responses) after 8 weeks of
treatment with fluoxetine (Fu et al, 2004), sertraline (Sheline
et al, 2001) and bupropion (Robertson et al, 2007), and after
16 weeks of cognitive behavioral therapy (Fu et al, 2008).
Davidson et al (2003) additionally reported a normalization
of abnormal functional deactivations in MDD patients in
response to aversive visual stimulation after 8 weeks of
venlafaxine treatment. All in all, taken with our own
findings, these studies appear to suggest a global effect of
successful treatment on restoring the equilibrium within the
complete pattern of brain activation and deactivation
responses to distinct types of aversive stimulation.
Research evidence suggests the participation of the
subgenual ACC and surrounding medial regions in both
self-referential attention (mentioned above) and in guiding
behavior and mood regulation through its influence on
autonomic, endocrine, and visceral functions (Drevets et al,
2008b; Paus, 2001; Price, 1999). The main afferents to this
neuroanatomic region come from the amygdala, ventral
striatum, thalamus, and brainstem monoamine nuclei
(Paus, 2001). The subgenual ACC and extended medial
prefrontal regions, in turn, send dense projections to the
periaqueductal gray matter and, especially, to the hypotha-
lamus, where these projections synapse with neurons
projecting to the brainstem and spinal autonomic centers
(Barbas et al, 2003). Structural and functional abnormalities
of the subgenual ACC have been extensively reported in
depressive patients (reviewed by Drevets et al, 2008b), and
have been frequently associated with MDD symptom
severity (Chen et al, 2007; Greicius et al, 2007; Matthews
et al, 2009). Previous research has shown the capacity of a
wide variety of antidepressant treatment strategies to
modulate and normalize functional alterations in the
subgenual–pregenual ACC and extended regions within
the medial frontal cortex (for relevant examples, see Drevets
et al, 2002; Mayberg et al, 2000, 2005; Nahas et al, 2007).
This study shows the association of duloxetine treatment
with significant changes in subgenual ACC and adjacent
areas involving the normalization of altered baseline
responses to aversive painful stimulation. The observed
pattern of functional changes suggests that our imaging
strategy is also useful in assessing this critical region in
MDD.
Symptomatic improvement after 8 weeks of duloxetine
treatment was associated with treatment-related activation
reductions in specific regions and with a paradoxical
enhancement in subjective perception of experimental pain.
Importantly, functional changes in the right prefrontal
cortex, which has been specifically involved in mediating
negative affect particularly in the context of MDD
(Davidson et al, 2002; Davidson, 2002; Liotti and Mayberg,
2001), were associated with improvement in core emotion
symptoms of depression. Activation reductions in the pons
were significantly correlated with improvement in somatic
complaints and were specifically associated with clinical
remission. In a recent study, Milak et al (2009) reported
a specific relationship between baseline metabolic activity
in the pons–midbrain region and clinical remission after
12 weeks of pharmacological treatment, which gives greater
consistency to this pontine finding. In addition, Mayberg
et al (2002) showed a pattern of metabolic changes in the
pons, specifically in positive responders to fluoxetine that
did not appear in the placebo responder group, which may
suggest that functional changes in the region are more
plausibly attributable to specific psychotropic effects of
the drug.
The painful stimulation paradigm used here has success-
fully provided imaging biomarkers of positive clinical
response to duloxetine treatment in MDD patients. Although
there is no previously published study on brain functional
predictors of positive clinical outcome associated with
duloxetine, our findings are highly coincident with imaging
literature showing the important role for the subgenual–
pregenual ACC and extended medial prefrontal areas
and, albeit to a lesser extent, dorsolateral prefrontal
regions, in predicting clinical responses to various treat-
ment modalities in MDD (Brockmann et al, 2009; Chen
et al, 2007; Davidson et al, 2003; Dougherty et al, 2003;
Keedwell et al, 2010; Little et al, 2005; Mayberg et al, 1997;
Mottaghy et al, 2002; Saxena et al, 2003; Siegle et al, 2006;
Wu et al, 1999).
Interestingly, MDD patients at baseline showed a
tendency to report reduced subjective experimental pain
scores, an effect that was reversed after 8 weeks of
treatment. MDD research has provided evidence for the
paradoxical phenomena of increased somatic complaints in
depressive patients paralleled by decreased pain perception
during externally delivered painful stimulation on the skin
(mainly thermal and electrical stimuli; Ba¨r et al, 2003; 2005;
2007; Dickens et al, 2003; Lautenbacher et al, 1994, 1999). In
contrast, MDD patients may show hyperalgesia for deep
somatic pain modalities such as muscle ischemia (Ba¨r et al,
2005). Such data may suggest an increased processing of
internal somatic and visceral afferent stimulation in MDD
congruent with enhanced self-focused attention that may be
paralleled by a reduction of brain attentional resources
destined to external stimulation, including painful stimuli.
Considering the above-mentioned role of the subgenual
ACC in maintaining self-focused attention, baseline deac-
tivation reductions in this region fit well with the observed
opposite tendencies found for sensitivity to internal and
external pain in MDD patients. Coherently, antidepressant
treatment with duloxetine was associated with normal-
ization of the abnormally absent subgenual ACC deactiva-
tion, and with both an increase in experimental pain
sensitivity and a reduction in somatic pain complaints.
Moreover, a specific correlation was found at week 8
between greater deactivation magnitudes in this region and
higher experimental pain ratings in MDD.
Reductions in right frontal cortex responses to pain from
baseline to week 8 in MDD patients were significantly
associated with both an increase in subjective experimental
pain perception and a decrease in core emotional symptoms
of depression. In the context of the discussed paradox, it
may indeed be relevant to mention that treatment-related
activation reductions (associated with subjective pain
score increases) were not observed in brain regions
specifically devoted to the encoding of subjective pain
perception (which has been mostly attributed to primary
somatosensory area, dorsal ACC, and specific portions of
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the insula; Hofbauer et al, 2001; Peyron et al, 2000; Rainville
et al, 1997). Apart from the previously mentioned role of the
subgenual ACC in the recovery of sensitivity to externally
induced pain on the skin, the relevant role of the right
prefrontal cortex in modulatingFie, reducingFpain per-
ception in natural and experimentally modified attentional
and expectation contexts (eg, placebo analgesia or distrac-
tion while performing another cognitive task) has been
widely suggested in previous pain neuroimaging literature
(Lieberman et al, 2004; Lo´pez-Sola` et al, 2010; Lorenz et al,
2003; Petrovic et al, 2000; Peyron et al, 1999; Salomons et al,
2004, 2007; Wager et al, 2004; Wiech et al, 2006, 2008b).
Coherently, three studies have shown enhanced prefrontal
activations associated with reduced experimental pain
subjective scores in three distinct psychiatric populations,
MDD, adjustment disorder and borderline personality
disorder (Ba¨r et al, 2006, 2007; Schmahl et al, 2006). Our
study may further inform as to the neural basis of the
inverse relationship between sensitivity to experimental
pain and core emotional symptoms of depression by
suggesting a crucial role for the right prefrontal cortex
(and also partly the subgenual ACC) in mediating both the
core antidepressant effects and the changes in subjective
pain perception. The experimental animal study by Jochum
et al (2007) showed, in agreement with our data, that
treatment with the SSRI citalopram for 8 weeks significantly
increased the sensitivity to thermal pain in anxious/
depressed rats that had a significant baseline hypoalgesia
for this painful stimulation modality.
Although we used a comparison group of healthy subjects
to control for task-repetition effects over time on brain
activation changes, we cannot estimate the influence of
placebo effects on the observed results. The absence of a
placebo patient group constitutes a relevant limitation of
the study, which was considered insurmountable in our
clinical context on the grounds of both patient severity and
the long period that would have been required without
administering effective treatment. Nevertheless, the rate of
clinical response and remission achieved following 8 weeks
of duloxetine treatment suggest the existence of a significant
antidepressant effect beyond placebo (Gupta et al, 2007).
In addition, treatment-related activation changes were
observed after 8 weeks of duloxetine in certain regions
(pons and anterior insula) previously shown to be targeted
by effective fluoxetine treatment, but not modified in
positive placebo responders (Mayberg et al, 2002), thus
providing our results with greater drug specificity.
It is relevant to mention that we used a relatively lenient
statistical threshold (as in most studies of this type) to test
for treatment effects and the correlations between brain
response changes and clinical variables. Admittedly, the
adopted criteria only partially control for the potential type
I statistical error and we should be cautious in the overall
interpretation of our results. However, it is also relevant to
emphasize that our analyses were comprehensive including
three assessments across time and between-group compar-
isons together with correlation analyses between activation
changes and clinical treatment effects in the patient group.
The intrastudy remarkable coherence between all the
results, their consistency with previous research in MDD,
and the anatomic plausibility of the findings may poten-
tially reduce the overall risk of drawing conclusions based
on false-positive data. Finally, it would have been of interest
to additionally use a nonpainful reference task (such as a
sadness induction paradigm) or an fMRI resting-state
assessment to perform a direct comparison of the effects
of duloxetine on pain-related neural responses with the
effects on MDD abnormalities in brain function more
primarily associated with core emotional alterations in
depressive patients.
As an original approach, painful stimulation as a basic
neural stressor proved to be effective in mapping brain
response changes associated with antidepressant treatment
and brain correlates of symptom improvement in regions of
special relevance to MDD pathophysiology. Using this fMRI
strategy, we assessed the effect of duloxetine in MDD for the
first time by means of neuroimaging. Although placebo
effects could not be accounted for, the presented results
may further contribute to characterizing the functional
brain changes associated with recovery from depression.
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